Actigrip

Quick links to important sections

Actigrip

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Actigrip

Quick Facts

Property Description
Active Ingredients Paracetamol, Pseudoephedrine, Triprolidine
Form Oral tablets or capsules
Pharmacological Class Analgesic, Decongestant, and Antihistamine Combination
Common Use Symptomatic relief of common cold and flu
Origin Synthetic combination drug

Actigrip: What It Is and How It's Classified

Actigrip is a globally recognized, synthetic fixed-dose combination (FDC) drug designed for the temporary relief of cold and flu symptoms. This product is classified within the unique Pharmacological Class of multi-action cold remedies that address pain, fever, and respiratory symptoms simultaneously. Actigrip is an Over-The-Counter (OTC) medicine, making it readily available for adults and adolescents seeking to manage acute discomfort associated with upper respiratory tract infections. These combinations are widely used for managing cold symptoms, especially when nasal congestion is present.


What Active Ingredients Does Actigrip Contain?

The efficacy of Actigrip stems from its inclusion of three primary active pharmaceutical ingredients (APIs): Paracetamol (a non-narcotic analgesic and antipyretic), Pseudoephedrine (a nasal decongestant), and Triprolidine (a first-generation antihistamine). Paracetamol is recognized for its ability to reduce fever and mild pain. The inclusion of Triprolidine is a differentiating feature, as this component is specifically added to address symptoms like sneezing and runny nose often associated with rhinitis and colds, offering a comprehensive symptomatic solution.


Actigrip's Primary Therapeutic Goal

The core therapeutic goal of Actigrip is the alleviation of the disruptive symptoms associated with the common cold and influenza. The combination is recognized for targeting the spectrum of discomfort, specifically addressing the simultaneous occurrence of nasal obstruction, pain, and fever. This symptomatic approach aims to improve patient comfort and allow the patient to manage daily activities while the body fights the underlying infection.

Regulatory References

  1. EMA Referral: Pseudoephedrine-containing medicinal products

What side effects are possible with Actigrip?

Possible side effects and safety information

The official regulatory safety profile for this combination medicine classifies adverse reactions by frequency and the body system affected, reflecting the combined actions of its three components.

Adverse Reaction Scope

Classification Area Documented Characteristics (Official Labeling)
Frequency (Common) Drowsiness, sedation, insomnia, nervousness, and dry mouth are frequently listed adverse reactions.
System-Organ Classes Effects are documented across Nervous System Disorders (e.g., dizziness), Psychiatric Disorders (e.g., agitation, anxiety), Cardiac Disorders (e.g., tachycardia, palpitations), Vascular Disorders (e.g., hypertension), and Renal/Urinary Disorders (e.g., urinary retention).
Serious Adverse Reactions Regulatory documents highlight the risk of Severe Hepatic Toxicity associated with the paracetamol component, increasing with dose. Rare but serious cerebrovascular events, specifically Posterior Reversible Encephalopathy Syndrome (PRES) and Reversible Cerebral Vasoconstriction Syndrome (RCVS), are documented safety concerns linked to the pseudoephedrine component.
Population-Specific Notes The label specifies that older adults may have an increased susceptibility to CNS effects, such as sedation and confusion, and an elevated risk of urinary retention. Patients with pre-existing severe hepatic impairment or severe uncontrolled hypertension are also noted for heightened risk.
Safety Restrictions Use is formally restricted in patients with severe uncontrolled hypertension, severe coronary artery disease, or severe acute or chronic kidney disease due to documented safety limitations.

Regulatory Safety Summary

The safety profile is structured to formally categorize adverse events and define product limitations. Drowsiness and sedation are generally reported as most prominent during the initial phase of treatment. The risk of severe adverse effects, particularly those affecting the liver and cardiovascular system, is related to the cumulative dose of components and the presence of underlying health conditions.

Overdose and Emergency Response

Overdose and When to Seek Help — Official Regulatory Information

The official overdose profile for this combination drug addresses the potential toxicity from its three active ingredients, mandating immediate emergency action due to the risk of severe, life-threatening outcomes.

System Documented Overdose Manifestations
Hepatic / Metabolic Nausea, Vomiting, Pallor, Abdominal pain (early onset); delayed onset of liver damage, liver failure, hepatic encephalopathy, and metabolic acidosis.
CNS / Cardiovascular Confusion, Hallucinations, Restlessness, Tremors, Seizures/Convulsions, Tachycardia, Palpitations, and Hypertension.

Mandated Emergency Actions:

  • Seek immediate medical attention and/or contact emergency services at once, even if initial symptoms are not present. Immediate medical management is required in all suspected overdose situations.
  • The specific antidote for Paracetamol toxicity, N-acetylcysteine (NAC), is required for treatment and is most effective when administered quickly.
  • Procedures such as Gastric Lavage and ongoing general supportive care are documented measures for managing overdose.
  • Urgent hospital referral is required for monitoring, including assessment of plasma Paracetamol concentrations against a nomogram to determine the severity and the need for antidote treatment.

Special Considerations:

Regulatory documents note that overdose is of particular concern in young children. Increased hazards of severe liver toxicity are specified for patients with non-cirrhotic alcoholic liver disease.

Summary: Regulatory guidelines define the acute risk from central nervous system and cardiac excitement, combined with the delayed but catastrophic risk of Paracetamol-induced hepatotoxicity. Therefore, immediate expert medical intervention is mandatory to mitigate these documented severe outcomes.

Therapeutic Uses of Actigrip

What Actigrip Treats: Main Uses and Benefits

Actigrip is generally used as supportive symptom management during acute episodes of the common cold and flu-like illness, applied in addressing symptom clusters that may become intense or disruptive. The medication is considered relevant for easing symptoms associated with systemic imbalance and heightened physiological activity, which contributes to easing the overall symptom burden. The combination is relevant for easing symptoms that often interfere with daily functioning.

The medication is applied across therapeutic domains where short-term symptom management is appropriate, particularly when symptoms related to physical discomfort and irritative states occur together. This involves managing symptoms such as headaches, generalized body aches, and fever, alongside addressing nasal manifestations like obstruction, runny nose (rhinorrhea), and sneezing.

This supportive approach may assist with managing symptoms that often interfere with daily functioning, contributing to improved comfort during phases of increased distress or discomfort.

Quick Fact: Relief for Multi-Symptom Discomfort
Symptom Axes Targeted Pain, Fever, Nasal Congestion, Runny Nose
Typical Context Acute, Transient Cold/Flu Episodes
Core Therapeutic Benefit Easing overall symptom burden and supporting comfort

Regulatory References

  1. DailyMed drug label for Pseudoephedrine/Triprolidine

Eligibility and Restrictions for Use

Who Can and Cannot Use Actigrip?

This section defines the official population eligibility and non-eligibility rules for Actigrip (Paracetamol, Pseudoephedrine, Triprolidine) as established by regulatory authorities.

Category Official Regulatory Statement
Populations for whom use is allowed Adults and Adolescents ge 12 years of age.
Populations for whom use is contraindicated Children under mathbf12 years of age.
Conditions Prohibiting Use Patients with severe renal failure, hypertension, diabetes mellitus, hyperthyroidism, phaeochromocytoma, and closed-angle glaucoma.
Drug History Prohibition Individuals currently taking Monoamine Oxidase Inhibitors (MAOIs) or within 14 days of stopping them.
Physiological Status Contraindicated during pregnancy and breastfeeding.

Regulatory documents structure the eligibility profile by defining clear absolute contraindications based on age, pre-existing conditions, and concurrent medication use. Use is also restricted, requiring caution, in patients with severe hepatic insufficiency and the elderly, where appropriate minimum dosages must be observed. The framework ensures the drug is used only in populations where its safety profile is deemed acceptable under labeled conditions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents classify the medicine's interactions based on the activity of its three components, leading to specific restrictions and contraindicated combinations.

Classification Documentation Point
Contraindicated Combinations Co-administration with Monoamine Oxidase Inhibitors (MAOIs), including for 14 days after stopping MAOI treatment, is strictly prohibited. Other restricted substances include sympathomimetic agents (e.g., decongestants, appetite suppressants) and certain antihypertensive drugs (e.g., Methyldopa, Guanethidine).
Pharmacodynamic Risk The Triprolidine component leads to additive CNS depression when combined with Central Nervous System (CNS) Depressants, including alcohol, opioids, and hypnotics. The Pseudoephedrine component carries the risk of pressor effects and ventricular arrhythmias with co-administration of Halogenated Anaesthetic Agents.
Pharmacokinetic Risk The metabolism of Paracetamol may be accelerated via hepatic enzyme induction when co-administered with certain anticonvulsant drugs (e.g., Carbamazepine, Phenobarbital) and oral contraceptives. This may alter drug exposure and increase toxicity risk.

The official interaction profile is characterized by mandatory restrictions and prohibitions to manage the combined cardiovascular risks from Pseudoephedrine and the sedative potentiation from Triprolidine. Precautions also exist for the altered plasma levels of Paracetamol when taken with substances known to induce hepatic monooxygenases.

Mechanism of Action

The effect profile of this combination product arises from three distinct, yet complementary, pharmacodynamic mechanisms. Each active component targets a specific biological domain, leading to the concurrent modulation of three separate physiological responses.


Modulating Central Thermoregulation and Pain Signaling

This mechanism, primarily driven by Paracetamol, involves the inhibition of specific Cyclooxygenase (COX) enzyme activity predominantly within the Central Nervous System (CNS), particularly the hypothalamus. This action modulates the signaling of **Prostaglandin E2 ( PGE2) at key neural centers, an action that lowers the elevated thermoregulatory set point and activates descending pathways that result in an increase in the pain threshold.


alpha1 Adrenergic Modulation of Nasal Vascular Tone

This domain is defined by the action of Pseudoephedrine, which functions as both a direct and indirect agonist of Alpha-1 (alpha1) Adrenergic Receptors located on the smooth muscle of nasal mucosal blood vessels. Activating these receptors initiates a signal cascade resulting in vasoconstriction . The vasoconstriction produced by this cascade decreases blood volume and capillary fluid extravasation in the nasal tissues.


Competitive Blockade of Histamine H1 Receptors

This mechanism is mediated by Triprolidine, which acts as a competitive antagonist of the Histamine H1 Receptor in both peripheral tissues and the CNS. By binding to these receptors, the drug suppresses histamine's ability to trigger its physiological effects. This suppression of histamine binding prevents the mediator's downstream effects, including increased glandular fluid secretion and heightened vascular permeability.

Dosage and Administration Information

How to Use Actigrip

Actigrip is administered exclusively via the oral route as a fixed-dose combination tablet. The general principle for use is based on strict adherence to dose, frequency, and duration limitations to ensure proper administration of the combination's active ingredients: Paracetamol, Pseudoephedrine, and Triprolidine.


Official Administration Guidelines

Entity Instruction
Route of administration: Oral route only.
Dosing schedule (Adults): One tablet per dose. The maximum daily intake of Paracetamol from all sources should not exceed 4 g.
Timing in relation to meals: The tablets must be taken on a full stomach.
Frequency pattern: Multiple daily doses (typically 2 to 3 times per day).
Course duration (Adults): Treatment is strictly limited to a maximum of 5 continuous days.
Course duration (Adolescents): Use for those aged 12 to 18 years is limited to a maximum of 3 continuous days.
Special procedural conditions: The recommended dose, frequency, and duration must not be exceeded.

Connection to the Overall Use Protocol

This medication is defined for short-term use, and the established protocol involves a precise oral route, coupled with a specific maximum daily dose and frequency pattern of two to three times daily. The mandatory instruction to take the tablets on a full stomach provides a key administration condition, while the strictly enforced duration limits define the entire course of therapy for both adults and adolescents. These structured requirements constitute the standardized approach for administration.

Recent Clinical Evidence

Actigrip: Recent Clinical Evidence

The research for Actigrip, a fixed-dose combination of Paracetamol, Pseudoephedrine, and Triprolidine, involves studies examining the combination in the context of multiple discomforts associated with the common cold and flu-like illnesses. The evidence base primarily consists of short-term clinical trials, often utilizing Randomized Controlled Trials (RCTs) to assess outcomes related to physical discomfort and daily functioning.


Evidence for Symptomatic Relief

These studies mainly included adults and older children with recent-onset cold symptoms. Researchers monitored changes in key symptom axes, including nasal congestion, runny nose, pain, and fever. Findings describe patterns observed in patient-reported outcomes regarding perceived discomfort. Since the product is a combination, the evidence may rely on trials for two-component formulas or the individual active ingredients, and the certainty about the magnitude of the measured change for every symptom may remain moderate.


Study Duration and Research Gaps

Comparative studies have examined the combination against placebo or single active ingredients to understand monitored patterns. Follow-up durations for these clinical trials were typically limited, spanning only the acute phase of the illness (usually 2 to 10 days). Long-term effects are not fully established, and evidence for use beyond the acute phase is limited.


Limitations and Specific Patient Groups

Data for certain groups remain insufficient. For instance, few data are available for older adults or for individuals with complex, underlying health conditions (co-morbidities) where evidence is limited. The evidence for the specific three-component formula is often heterogeneous across different studies. Overall, research provides context but not individual predictions, and evidence highlights what is known—and what is still uncertain—about the combination's application in managing the full spectrum of cold symptoms.

Key Studies & References Pseudoephedrine Hydrochloride and Triprolidine Hydrochloride tablet (DailyMed, NIH)

Frequently Asked Questions (FAQ)

Common questions about Actigrip (FAQ)


Q: How quickly does Actigrip usually start working?

A: Official product information suggests that the effects of the active ingredients should become noticeable within a typical, short time frame after administration. Since the product is used for symptomatic relief of acute cold symptoms, a relatively fast onset is generally expected from its components, which include an analgesic (pain reliever) and a decongestant.

Q: What is the typical time frame that Actigrip effects last?

A: The official regulatory dosing schedule indicates that Actigrip is typically taken multiple times per day (2 to 3 times). This frequency is generally based on the components' intended duration of relief, which typically lasts for several hours.

Q: Is Actigrip known to cause drowsiness?

A: Yes, regulatory documents list both drowsiness and sedation as frequently reported common adverse reactions. This effect is primarily linked to the Triprolidine component, which is a first-generation antihistamine associated with these effects.

Q: Are there any common foods or drinks that interact with Actigrip?

A: Official instructions specify that the tablets must be taken on a full stomach. While no specific common foods are strictly prohibited, alcohol is specifically documented in regulatory information to be avoided due to the risk of additive central nervous system depression when combined with the antihistamine component.

Q: What is the difference between Actigrip and a single-ingredient flu medicine?

A: Actigrip is defined as a fixed-dose combination containing three active ingredients: an analgesic (Paracetamol), a decongestant (Pseudoephedrine), and an antihistamine (Triprolidine). This combination is designed to address multiple cold symptoms simultaneously, unlike a single-ingredient medicine that would focus on only one primary symptom, such as fever or cough.

Q: Is it normal to feel dry mouth after taking Actigrip?

A: Yes, dry mouth is listed in the official product labeling as a common adverse reaction. The occurrence of dry mouth is a recognized side effect associated with the antihistamine component of the medicine.

Q: Does Actigrip interact with common anti-anxiety medications?

A: Regulatory information indicates that the Triprolidine component may cause additive central nervous system (CNS) depression when combined with other CNS depressants. Since many common anti-anxiety medicines fall into this class, this combination is associated with an increased risk of effects like sedation and drowsiness.

Q: Are there any known severe allergic reactions associated with Actigrip?

A: Regulatory documents highlight the rare but serious possibility of severe skin reactions, including Erythema Multiforme, Stevens-Johnson Syndrome (SJS), and Toxic Epidermal Necrolysis (TEN), which have been reported, primarily associated with the Paracetamol component.

Q: Can people with liver issues use Actigrip?

A: Use is strictly contraindicated (prohibited) for patients with severe liver problems. For individuals with less severe hepatic issues, the official label advises that caution must be exercised and the minimum effective dosage should be observed.

Q: Can Actigrip be taken at the same time as cough syrup?

A: Co-administration with other sympathomimetic agents is strictly prohibited by regulatory bodies. Since some cough syrups contain decongestants (which are sympathomimetic agents), regulatory guidance indicates that combining them with Actigrip should be avoided due to the potential for excessive cardiovascular or pressor effects.

Q: Is Actigrip known to interact with caffeine?

A: The official product labeling does not explicitly name caffeine. However, Actigrip contains Pseudoephedrine, which is a stimulant. Combining it with caffeine may lead to additive central nervous system stimulation, potentially increasing effects like nervousness and high blood pressure.

Q: Is Actigrip safe to take if I'm already taking a blood thinner?

A: The Paracetamol component is noted in regulatory documents to interact with certain anticoagulants (blood thinners), such as warfarin. Co-administration with blood thinners is associated with an increased potential for interaction, requiring caution.

Q: Is there a limit on how many days in a row Actigrip can be used?

A: Yes, the maximum duration for continuous use is strictly limited by regulatory administration guidelines. Treatment is typically limited to a maximum of 5 continuous days for adults and 3 continuous days for adolescents. This restriction ensures the medicine is used only for short-term, acute symptom relief.

Q: What happens if I take Actigrip too close to bedtime?

A: Taking Actigrip close to bedtime may lead to sleep disturbances. The product contains ingredients that can cause adverse reactions such as insomnia, nervousness, and agitation, which are effects that can interfere with the ability to fall or stay asleep.

Q: How does Actigrip address both pain and congestion?

A: Actigrip manages multiple symptoms through its combination of active ingredients, each with a different mechanism. Pain and fever are addressed by Paracetamol. Nasal congestion is addressed by Pseudoephedrine, which acts to narrow blood vessels in the nasal lining, thus reducing swelling and facilitating breathing.

Q: Is the antihistamine component in Actigrip the same as other common allergy pills?

A: The antihistamine in Actigrip is Triprolidine, which is classified as a first-generation antihistamine. This is chemically distinct from the second-generation antihistamines found in many common, non-drowsy allergy pills. First-generation antihistamines typically have a higher potential for side effects such as drowsiness.

Q: What happens if I miss a scheduled time for Actigrip?

A: Official product leaflets for cold medicines generally advise that if a dose is missed, general protocols suggest resuming the medicine at the next regular time, ensuring the minimum time interval between doses is respected. Users should never take a double dose to make up for the one missed.

Q: Can Actigrip affect my sleep?

A: Yes, official safety documents list sleep disturbances as common adverse reactions. The product's components have been associated with adverse reactions that include both insomnia or nervousness and sedation or drowsiness.

Q: Why does Actigrip sometimes make people feel jittery?

A: The feeling of being 'jittery' is a manifestation of the documented adverse reactions of nervousness and agitation. These effects are linked to the stimulating properties of the Pseudoephedrine component, a sympathomimetic agent that acts on the nervous system.

Q: Can Actigrip cause stomach upset?

A: Gastrointestinal side effects such as stomach upset are not listed among the most frequently reported adverse reactions in the primary regulatory safety summaries.

Q: Does Actigrip contain aspirin?

A: No. Official regulatory documents list the active ingredients as Paracetamol, Pseudoephedrine hydrochloride, and Triprolidine hydrochloride. Aspirin (Acetylsalicylic Acid) is not included in the composition of this fixed-dose combination.

Q: Are there any common supplements that should be avoided while using Actigrip?

A: Official interaction profiles list specific drugs but do not broadly address all common supplements. Regulatory guidance indicates that general caution is warranted regarding any supplement that may affect liver function (due to Paracetamol) or has stimulating effects on the central nervous system (due to Pseudoephedrine).

Q: Are there different versions of Actigrip (e.g., day/night formulas)?

A: Official product information confirms that other formulations exist under the name 'Actigrip Day & Night.' This is a separate product that uses a different composition, typically replacing the stimulating component for night-time use.

Q: What kind of research evidence supports the use of Actigrip for cold symptoms?

A: The research evidence primarily consists of short-term clinical trials, often Randomized Controlled Trials (RCTs). These studies have monitored patient-reported outcomes for key cold symptoms such as nasal congestion, runny nose, pain, and fever, supporting its therapeutic goal of symptomatic relief.

Q: Do official documents mention any potential for dependence with Actigrip?

A: While the term 'dependence' is not explicitly used, official product information notes a risk of abuse associated with the Pseudoephedrine component. Continuous use of this component may lead to tolerance, and users should adhere strictly to recommended administration limits.

Q: What is the general expectation for relief when using Actigrip for a cold?

A: The official therapeutic goal is defined as the alleviation of disruptive symptoms associated with the common cold and influenza. The general patient expectation is for an improvement in overall comfort and the ability to manage daily activities while the body resolves the underlying infection.

Q: Is Actigrip considered effective for allergy-related symptoms?

A: Actigrip is primarily indicated for the symptomatic relief of the common cold and flu. However, it contains Triprolidine, an antihistamine which is clinically recognized for addressing symptoms like sneezing and runny nose that can occur due to either a cold or allergic rhinitis.

Q: Do official documents describe how Actigrip should be stored?

A: Yes, official regulatory guidelines require that the product be stored under specific conditions to maintain its integrity. This generally means storing the medicine in a dry place at a temperature not exceeding 25 C (77 F), away from humidity and light.

Q: Is there any research on long-term effects of using Actigrip?

A: Clinical trials conducted for the medicine focused on the acute phase of illness, typically spanning only a short duration (2 to 10 days). Official summaries confirm that long-term effects are not fully established, and evidence for use beyond the acute phase is currently limited.

How should Actigrip be stored and disposed of?

How to Store and Dispose of Actigrip — Official Regulatory Information

Official regulatory guidelines mandate specific storage and disposal requirements for Actigrip, primarily due to its classification as a highly flammable liquid and its potential toxicity to aquatic life.

Storage and Handling

Requirement Official Statement
Flammability Protection Store strictly away from heat, hot surfaces, sparks, open flames, and other ignition sources.
Container Integrity The container must be kept tightly closed to prevent the release of flammable vapor and to protect contents from humidity and light.
Child Safety Keep the medicine in a location out of the reach of children and pets.

Disposal Instructions

Disposal must prioritize the official take-back hierarchy. If no take-back option is available, the product must be removed from its original container, mixed with an undesirable substance (such as dirt or cat litter), placed in a sealed bag or container, and then discarded in the household trash. Avoid release to the environment to prevent contamination, and always scratch out personal information on packaging before disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Actigrip found in:

A-Z Index: